[Ip-health] DNDi Special Session on the Essential Health R&D Resolution 59.24 at Global Forum, Mon, 30 Oct: 18h00-19h30

[Ann-Marie Sevcsik]

This is a multi-part message in MIME format.
--
We will also have a marketplace booth: all ip-health'ers are welcome if the=
y are attending.

Special Session for Global Forum 10, Cairo
Neglected Diseases: Supporting the Global Framework on Essential Health R&D
Monday, 30 October: 18h00 to 19h30
Conrad Cairo Hotel

The need for increased support of essential innovation for neglected diseas=
es is a growing global concern. Governments are being urged to lose no more=
 time in supporting new funding mechanisms for neglected disease research a=
nd development and create a favourable environment to stimulate (R&D). A ha=
ndful of "Innovative Developing Countries" are becoming more proactive in t=
he field of drug R&D. Yet innovation in drug discovery for neglected diseas=
es remains a critical gap.=A0 In May, the 192-member WHA approved a resolut=
ion that established a working group to draft a global strategy on intellec=
tual property, health research and development, and new medicines for disea=
ses that especially affect developing countries. These are small but positi=
ve steps towards addressing the greater problem of R&D for neglected diseas=
es. Much more remains to be done. A distinguished panel of speakers will di=
scuss various aspects of this issue.


Chair: Dr Rob Ridley, Director Special Programme for Research and Training =
in Tropical Diseases (TDR)

Speakers:
* Davy K.Koech, Director, Kenya Medical Research Institute
=A0=A0=A0=A0 Public leadership in Kenya: setting R&D priorities for neglect=
ed diseases

* Yves CHAMPEY, Chair Board of Directors
Drugs for Neglected Diseases Initiative
=A0=A0=A0=A0 Increased public sector support of R&D to bring true innovatio=
n to the discovery process

* Carlos MOREL, Scientific Director, FIOCRUZ Foundation
Crucial role and input of 'Innovative Developing Countries' to reinforce dr=
ug R&D for neglected diseases

* Paulina TINDANA, Patient Representative, DNDi Board of Directors
=A0=A0=A0=A0 Importance of government support in delivering new drugs for n=
eglected diseases


***************************************************************************
Ann-Marie Sevcsik
Press Officer / Medical Writer
Drugs for Neglected Diseases initiative
1 Place St Gervais
1201 Geneva
Switzerland
+41=A0(0)22 906 9230/50 (office/direct)
+41 (0)79 814 9147 (mobile)
+ 41(0)22 906 9231 (fax)
amsevcsik@dndi.org
www.dndi.org
=A0

--
Content-Description: Ann-Marie Sevcsik .vcf

[ Ann-Marie Sevcsik .vcf of type text/x-vcard deleted ]